丁苯酞联合尤瑞克林对急性脑梗死患者颈动脉内膜中层厚度及血液流变学的影响
2020-06-19郭文敏郭喜玲和红霞
郭文敏 郭喜玲 和红霞



【摘要】 目的 觀察丁苯酞联合尤瑞克林对急性脑梗死(ACI)患者颈动脉内膜中层厚度(IMT)及血液流变学的影响。
方法 选择2017年1月~2019年5月治疗的ACI患者76例,按随机数字表分为两组,各38例。对照组接受尤瑞克林治疗,观察组则加用丁苯酞软胶囊治疗。比较两组临床疗效、美国国立卫生研究院卒中量表(NIHSS)评分、IMT、血液流变学指标[血浆黏度(PSV)、全血低切黏度(LSV)、全血高切黏度(HSV)]及不良反应。
结果 观察组总有效率为92.11%,高于对照组的73.68%,治疗后观察组NIHSS评分(4.13±1.36)分、PSV(1.26±0.50) mPa·s、HSV(4.11±1.89) mPa·s、IMT(1.12±0.10) mm,低于对照组的(6.37±1.72)分、(2.98±0.94)mPa·s、(5.58±2.04) mPa·s、(1.56±0.31) mm,差异有统计学意义(P<0.05);观察组、对照组不良反应发生率(10.53% VS 5.26%)相比,差异无统计学意义(P>0.05)。
结论 ACI患者接受丁苯酞软胶囊、尤瑞克林联合治疗有助于改善神经功能及血液流变学,降低IMT,在提高ACI治疗效果的同时,并未增加药物副作用。
【关键词】 急性脑梗死;丁苯酞软胶囊;尤瑞克林;NIHSS;颈动脉内膜中层厚度;血液流变学
中图分类号:R743.33 文献标志码:A DOI:10.3969/j.issn.1003-1383.2020.05.009
Effects of butylphthalide combined with urinary kallindinogenase on intima-media thickness and hemorheology in patients with acute cerebral infarction
GUO Wenmin,GUO Xiling,HE Hongxia
(Department of Neurology,Mengzhou People' s Hospital,Mengzhou 454750,Henan,China)
【Abstract】 Objective To observe the effects of butylphthalide combined with urinary kallindinogenase on carotid intima-media thickness(IMT) and hemorheology in patients with acute cerebral infarction(ACI).
Methods 76 cases of ACI patients treated from January 2017 to May 2019 were selected and divided into two groups according to random number table,with 38 cases in each group.The control group were treated with urinary kallindinogenase,and the observation group were treated with soft capsules of butylphthalide on the basis of the control group.And then,clinical efficacy,national institute of health stroke scale(NIHSS)score,IMT,hemorheological indexes[plasma viscosity(PSV),whole blood low shear viscosity(LSV),whole blood high shear viscosity(HSV)] and adverse reactions were compared between the two groups.
Results The total effective rate of the observation group was 92.11%,higher than that of the control group(73.68%).After treatment,NIHSS score (4.13±1.36),PSV (1.26±0.50) MPa·s,HSV (4.11±1.89) MPa·s and IMT (1.12±0.10) mm in the observation group were lower than those[(6.37±1.72),(2.98±0.94) MPa·s,(5.58±2.04) MPa·s and (1.56±0.31) mm] in the control group,difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions(10.53% VS 5.26%) between the observation group and the control group(P>0.05).
Conclusion The combination of butylphthalide soft capsule and urinary kallidinogenase can improve the neurologic function and hemorheology of patients with ACI,reduce IMT,and improve the therapeutic effect of ACI without increasing the side effects of drugs.
【Key words】 ACI;soft capsule of butylphthalide;urinary kallidinogenase;NIHSS;IMT;hemorheology
急性脑梗死(acute cerebral infarction,ACI)作为常见脑血管疾病,发生率已占脑血管病的75%~80%,致残、致死率较高[1]。ACI缺乏特效治疗方法,虽然溶栓治疗效果已获临床肯定,但其治疗时间窗窄,且易出现再灌注损伤等并发症,限制其进一步应用[2]。尤瑞克林属于脑血管扩张剂,丁苯酞软胶囊属于一种脑保护剂,两者单独用于ACI治疗已有数年,近年来有研究学者指出,将两者联合使用能够增强ACI治疗效果[3~4]。鉴于此,本研究将观察丁苯酞软胶囊联合尤瑞克林治疗对ACI患者颈动脉内膜中层厚度(intima-media thickness,IMT)及血液流变学的影响,现报告如下。
1 资料与方法
1.1 一般资料
选择2017年1月~2019年5月我院治疗的ACI患者76例,按随机数字表分为两组,均38例。……
